Dalzon Bastien, Lebas Célia, Jimenez Gina, Gutjahr Alice, Terrat Céline, Exposito Jean-Yves, Verrier Bernard, Lethias Claire
Institut de Biologie et Chimie des Protéines, Fédération de Recherche, SFR BioSciences (Unité Mixte de Service 3444/US8) Gerland-Lyon Sud, Université de Lyon 1, Lyon, France.
Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, Centre National de la Recherche Scientifique, Unité Mixte de Recherche, 7 passage du Vercors, Lyon, France.
PLoS One. 2016 Dec 14;11(12):e0167663. doi: 10.1371/journal.pone.0167663. eCollection 2016.
Biodegradable polymeric nanoparticles are vehicles of choice for drug delivery and have the ability to encapsulate and present at their surface different molecules of interest. Among these bio-nanocarriers, poly(lactic acid) (PLA) nanoparticles have been used as adjuvant and vehicle for enhanced vaccine efficacy. In order to develop an approach to efficient vaccine delivery, we developed nanoparticles to target α5β1 positive cells. We first overproduced, in bacteria, human fibronectin FNIII9/10 recombinant proteins possessing an integrin α5β1 binding site, the RGDS sequence, or a mutated form of this site. After having confirmed the integrin binding properties of these recombinant proteins in cell culture assays, we were able to formulate PLA nanoparticles with these FNIII9/10 proteins at their surface. We then confirmed, by fluorescence and confocal microscopy, an enhanced cellular uptake by α5β1+ cells of RGDS-FNIII9/10 coated PLA nanoparticles, in comparison to KGES-FNIII9/10 coated or non-coated controls. As a first vaccination approach, we prepared PLA nanoparticles co-coated with p24 (an HIV antigen), and RGDS- or KGES-FNIII9/10 proteins, followed by subcutaneous vaccine administration, in mice. Although we did not detect improvements in the apparent humoral response to p24 antigen in the serum of RGDS/p24 nanoparticle-treated mice, the presence of the FNIII proteins increased significantly the avidity index of anti-p24 antibodies compared to p24-nanoparticle-injected control mice. Future developments of this innovative targeted vaccine are discussed.
可生物降解的聚合物纳米颗粒是药物递送的首选载体,能够包裹并在其表面呈现不同的目标分子。在这些生物纳米载体中,聚乳酸(PLA)纳米颗粒已被用作佐剂和载体以提高疫苗效力。为了开发一种高效疫苗递送方法,我们制备了靶向α5β1阳性细胞的纳米颗粒。我们首先在细菌中过量表达具有整合素α5β1结合位点RGDS序列或该位点突变形式的人纤连蛋白FNIII9/10重组蛋白。在细胞培养试验中确认了这些重组蛋白的整合素结合特性后,我们能够制备表面带有这些FNIII9/10蛋白的PLA纳米颗粒。然后,通过荧光和共聚焦显微镜,我们证实,与KGES-FNIII9/10包被或未包被的对照相比,RGDS-FNIII9/10包被的PLA纳米颗粒被α5β1+细胞摄取的能力增强。作为第一种疫苗接种方法,我们制备了共包被有p24(一种HIV抗原)以及RGDS-或KGES-FNIII9/10蛋白的PLA纳米颗粒,随后在小鼠中进行皮下疫苗接种。尽管我们未检测到RGDS/p24纳米颗粒处理的小鼠血清中对p24抗原的明显体液反应有所改善,但与注射p24纳米颗粒的对照小鼠相比,FNIII蛋白的存在显著提高了抗p24抗体的亲和力指数。本文还讨论了这种创新型靶向疫苗的未来发展。